Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20,475 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
L-type amino acid transporter 1 inhibitor JPH203 prevents the growth of cabazitaxel-resistant prostate cancer by inhibiting cyclin-dependent kinase activity.
Rii J, Sakamoto S, Mizokami A, Xu M, Fujimoto A, Saito S, Koike H, Tamura T, Arai T, Yamada Y, Goto Y, Sazuka T, Imamura Y, Suzuki K, Kanai Y, Anzai N, Ichikawa T. Rii J, et al. Among authors: xu m. Cancer Sci. 2024 Mar;115(3):937-953. doi: 10.1111/cas.16062. Epub 2024 Jan 7. Cancer Sci. 2024. PMID: 38186218 Free PMC article.
Duration of androgen deprivation therapy and nadir of testosterone at 20 ng/dL predict testosterone recovery to supracastrate level in prostate cancer patients who received external beam radiotherapy.
Takei A, Sakamoto S, Wakai K, Tamura T, Imamura Y, Xu M, Maimaiti M, Kawamura K, Imamoto T, Komiya A, Akakura K, Ichikawa T. Takei A, et al. Among authors: xu m. Int J Urol. 2018 Apr;25(4):352-358. doi: 10.1111/iju.13521. Epub 2018 Jan 11. Int J Urol. 2018. PMID: 29323427
Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer.
Sakamoto S, Maimaiti M, Xu M, Kamada S, Yamada Y, Kitoh H, Matsumoto H, Takeuchi N, Higuchi K, Uchida HA, Komiya A, Nagata M, Nakatsu H, Matsuyama H, Akakura K, Ichikawa T. Sakamoto S, et al. Among authors: xu m. J Clin Med. 2019 Apr 11;8(4):489. doi: 10.3390/jcm8040489. J Clin Med. 2019. PMID: 30978937 Free PMC article.
Expression of L-type amino acid transporter 1 as a molecular target for prognostic and therapeutic indicators in bladder carcinoma.
Maimaiti M, Sakamoto S, Yamada Y, Sugiura M, Rii J, Takeuchi N, Imamura Y, Furihata T, Ando K, Higuchi K, Xu M, Sazuka T, Nakamura K, Kaneda A, Kanai Y, Kyprianou N, Ikehara Y, Anzai N, Ichikawa T. Maimaiti M, et al. Among authors: xu m. Sci Rep. 2020 Jan 28;10(1):1292. doi: 10.1038/s41598-020-58136-x. Sci Rep. 2020. PMID: 31992742 Free PMC article.
Functional analysis of LAT3 in prostate cancer: Its downstream target and relationship with androgen receptor.
Rii J, Sakamoto S, Sugiura M, Kanesaka M, Fujimoto A, Yamada Y, Maimaiti M, Ando K, Wakai K, Xu M, Imamura Y, Shindo N, Hirota T, Kaneda A, Kanai Y, Ikehara Y, Anzai N, Ichikawa T. Rii J, et al. Among authors: xu m. Cancer Sci. 2021 Sep;112(9):3871-3883. doi: 10.1111/cas.14991. Epub 2021 Jul 8. Cancer Sci. 2021. PMID: 34050700 Free PMC article.
The heavy chain of 4F2 antigen promote prostate cancer progression via SKP-2.
Maimaiti M, Sakamoto S, Sugiura M, Kanesaka M, Fujimoto A, Matsusaka K, Xu M, Ando K, Saito S, Wakai K, Imamura Y, Nakayama K, Kanai Y, Kaneda A, Ikehara Y, Ikeda JI, Anzai N, Ichikawa T. Maimaiti M, et al. Among authors: xu m. Sci Rep. 2021 Jun 1;11(1):11478. doi: 10.1038/s41598-021-90748-9. Sci Rep. 2021. PMID: 34075107 Free PMC article.
20,475 results
You have reached the last available page of results. Please see the User Guide for more information.